Serina Therapeutics (NYSE: SER) furnishes press release in Reg FD 8-K

Rhea-AI Filing Summary

Serina Therapeutics, Inc. filed a current report to furnish, rather than file, a press release dated September 9, 2025 under Item 7.01 (Regulation FD Disclosure). The press release is attached as Exhibit 99.1.

The company states that this information is not deemed filed or automatically incorporated by reference into any Securities Act registration statement unless specifically identified. The report clarifies that inclusion of the press release does not represent a determination that its contents are material or complete for investment decisions.

0001708599false00017085992025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 9, 2025

Serina Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

1-38519

82-1436829

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

601 Genome Way, Suite 2001

Huntsville, Alabama 35806

(Address of principal executive offices)

(256) 327-9630

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, par value $0.0001 per share

SER

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure

Attached hereto as Exhibit 99.1 is a press release dated September 9, 2025, for Serina Therapeutics, Inc. (the “Company”).

The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that, the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release, dated September 9, 2025, issued by Serina Therapeutics, Inc.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SERINA THERAPEUTICS, INC.
Date: September 9, 2025			By:			/s/ Steve Ledger
						Chief Executive Officer

FAQ

What did Serina Therapeutics (SER) report in this 8-K filing?

Serina Therapeutics filed an 8-K to furnish a press release dated September 9, 2025 as Exhibit 99.1 under Item 7.01. The filing itself does not describe the press release’s contents, only that it is provided for Regulation FD disclosure purposes.

What is the purpose of the Item 7.01 Regulation FD disclosure for Serina Therapeutics (SER)?

The Item 7.01 disclosure is used to furnish information under Regulation FD, promoting fair disclosure to the market. Serina uses this item to provide public access to its September 9, 2025 press release without treating it as formally filed with the SEC.

Is the Serina Therapeutics (SER) press release incorporated into its registration statements?

The company states the press release is furnished, not filed, and will not be incorporated by reference into any Securities Act registration statement unless a future document specifically identifies it as being incorporated by reference.

Does Serina Therapeutics (SER) consider the furnished information in this 8-K to be material?

The company expressly notes that furnishing this information does not constitute a determination that it is material or complete. It also clarifies that investors are not directed to rely solely on this information when making investment decisions.

Which exhibits are attached to Serina Therapeutics’ (SER) September 9, 2025 8-K?

The filing lists two exhibits: Exhibit 99.1, a press release dated September 9, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.